Clicky

Keros Therapeutics, Inc.(KROS)

Description: Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.


Keywords: Biopharmaceutical Organ Systems Hypertension Rare Diseases Disorders Bone Hematology Osteoporosis Therapeutic Products Anemia Pulmonary Arterial Hypertension Myelodysplastic Syndrome Skeletal Disorders Syndromes Genodermatoses Myelofibrosis Thrombocytopenia Blood Disorders Molecule Product Bone Disease Hematopathology Musculoskeletal Disorders Osteogenesis Imperfecta

Home Page: www.kerostx.com

KROS Technical Analysis

99 Hayden Avenue
Lexington, MA 02421
United States
Phone: 617 314 6297


Officers

Name Title
Dr. Jasbir S. Seehra Ph.D. Pres, CEO, Treasurer, & Director
Mr. Keith C. Regnante MBA Chief Financial Officer
Dr. Jennifer Lachey Ph.D. Chief Scientific Officer
Mr. Christopher Rovaldi M.Sc. Chief Operating Officer
Ms. Esther Cho J.D. Head of Legal & Corp. Sec.
Ms. Robin Wagner VP of HR
Dr. Simon Cooper MBBS Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.7412
Price-to-Sales TTM: 68.4176
IPO Date: 2020-04-08
Fiscal Year End: December
Full Time Employees: 104
Back to stocks